Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Stocks in this Quantisnow insightHealth Care
Historical context for IRD
Across the 25 sessions after earlier IRD headlines, the stock closed higher 13 times and lower 11 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IRD | SPY |
|---|---|---|---|
| Apr 6, 2026 | Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | +1.3% | +0.5% |
| Mar 30, 2026 | Cantor Fitzgerald initiated coverage on Opus Genetics with a new price target | +0.0% | -0.3% |
| Mar 24, 2026 | Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | -1.7% | -0.3% |
| Mar 16, 2026 | Oppenheimer initiated coverage on Opus Genetics with a new price target | +3.2% | +1.0% |
| Mar 10, 2026 | Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | +1.7% | -0.2% |
| Mar 3, 2026 | Opus Genetics to Present at Upcoming Investor Conferences in March 2026 | -1.8% | -0.9% |
Keep researching IRD
Quantisnow market dataNASDAQ
IRD
Opus Genetics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for IRD
Full IRD profile on Quantisnow Follow IRD and get a push notification the moment its next story breaks.